Table 1.

Prevalence of antibodies to HCV recombinant antigens and peptide epitopes in U.S. patient groups at high risk of HCV infection

HCV antigen (amino acid positions)% reactive samples in the following groups:
Paid blood donorsaPatients with posttransfusion** HCV infectionbIVDAsc
Core
 Recombinant polyprotein c22 (2–120)1892100
 Peptide epitope (10–53)1892100
E1
 Recombinant polyprotein e1 (192–380)125844
 Peptide epitope (303–320)95344
E2
 Recombinant polyprotein e2 (404–662)95533
 Peptide epitope (405–444)85331
NS4
 Recombinant polyprotein C100c (1569–1930)177169
 Epitope (1901–1940)135866
NS5
 Recombinant polyprotein NS5 (2054–2995)177482
 Peptide epitope (2278–2313)105369
MEFA-6 chimeric polypeptide2095100
  • a Samples collected in 1989 from paid blood donors (prior to the earliest HCV antibody screening assays) (n = 58).

  • b Samples from patients with confirmed HCV infection posttransfusion (n = 38).

  • c Samples from IVDAs with confirmed HCV infection (n = 39).